Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into ...
Sangamo Therapeutics, Inc. is focused on transl...
Catasys has contracted with leading national, regional and local health insurance ...
Catasys has contracted with leading national, r...
Acacia Diversified Holdings, Inc., is an emerging hemp company, through its wholly...
Acacia Diversified Holdings, Inc., is an emergi...
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...
Spectrum Pharmaceuticals is a leading biotechno...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a...
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to im...
Five Prime Therapeutics, Inc. discovers and dev...
We are a clinical stage biopharmaceutical company focused on the discovery, develo...
We are a clinical stage biopharmaceutical compa...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
Join the National Investor Network and get the latest information with your interests in mind.